Cargando…
In situ Protein Detection for Companion Diagnostics
The emergence of targeted therapies for cancer has created a need for the development of companion diagnostic tests. Assays developed in recent years are aimed at determining both the effectiveness and safety of specific drugs for a defined group of patients, thus, enabling the more efficient design...
Autores principales: | Gremel, Gabriela, Grannas, Karin, Sutton, Lesley Ann, Pontén, Fredrik, Zieba, Agata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814083/ https://www.ncbi.nlm.nih.gov/pubmed/24199171 http://dx.doi.org/10.3389/fonc.2013.00271 |
Ejemplares similares
-
ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer
por: Magnusson, Kristina, et al.
Publicado: (2016) -
Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects
por: Olsen, Dana, et al.
Publicado: (2014) -
A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer
por: Jørgensen, Jan Trøst, et al.
Publicado: (2021) -
Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics
por: Pant, Saumya, et al.
Publicado: (2014) -
Antibodies Biotinylated Using a Synthetic Z-domain from Protein A Provide Stringent In Situ Protein Detection
por: Andersson, Sandra, et al.
Publicado: (2013)